Feature Channels: Pharmaceuticals

Filters close
Released: 7-Jan-2014 12:00 PM EST
On-Demand Vaccines Possible with Engineered Nanoparticles
University of Washington

University of Washington engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.

18-Dec-2013 9:00 PM EST
Innovative Screening Strategy Swiftly Uncovers New Drug Candidates, New Biology
Scripps Research Institute

Scientists at The Scripps Research Institute have demonstrated a drug-discovery strategy with a double payoff—it enables the rapid selection of chemical compounds that have a desired effect on cells and also highlights how the compounds work.

Released: 20-Dec-2013 12:00 PM EST
2-Drug Combo Helps Adolescents With ADHD, Aggression
Ohio State University Wexner Medical Center

Prescribing both a stimulant and an antipsychotic drug to children with physical aggression and attention-deficit/hyperactivity disorder (ADHD), along with teaching parents to use behavior management techniques, reduces aggressive and serious behavioral problems in the children, according to esearchers at The Ohio State University Wexner Medical Center.

Released: 17-Dec-2013 1:00 PM EST
Performance-Enhancing Drug Use More Prevalent than Type 1 Diabetes or HIV Infection
Endocrine Society

A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs (PEDs). The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.

10-Dec-2013 10:00 AM EST
Pain Drugs Used in Prostate Gland Removal Linked to Cancer Outcome
Mayo Clinic

The methods used to anesthetize prostate cancer patients and control pain when their prostate glands are surgically removed for adenocarcinoma may affect their long-term cancer outcomes, a study led by Mayo Clinic has found.

6-Dec-2013 2:30 PM EST
Additional Drug Shows Promise for Women with Triple-Negative Breast Cancer
Dana-Farber Cancer Institute

In a nationwide study of women with “triple-negative” breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators will report at the 2013 San Antonio Breast Cancer Symposium.

Released: 13-Dec-2013 10:00 AM EST
Cholesterol Could Counteract Breast Cancer Treatment
Newswise

Common breast cancer treatments target tumors by blocking or reducing the levels of estrogen in the body. These treatments may be rendered ineffective in patients with high cholesterol, where tumors can rely on the estrogen-mimicking molecule 27HC as an alternative fuel source.

Released: 12-Dec-2013 10:00 AM EST
Diabetes Drugs Affect Hearts of Men, Women Differently
Washington University in St. Louis

Widely used treatments for type 2 diabetes have different effects on the hearts of men and women, even as the drugs control blood sugar equally well in both sexes, according to researchers at Washington University School of Medicine in St. Louis. The investigators used PET scans to measure heart and whole-body metabolism in patients taking common diabetes drugs.

9-Dec-2013 1:00 PM EST
Herceptin Plus Taxol Highly Effective in Low-Risk Breast Cancer
Loyola Medicine

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

Released: 10-Dec-2013 11:00 AM EST
Exercise Alleviates Sexual Side-Effects of Antidepressants in Women
University of Texas at Austin (UT Austin)

Exercise can benefit health and improve mood, and now new research shows that it has the potential to restore sexual desire and function in women adversely affected by sexual side effects related to antidepressant use.

   
5-Dec-2013 2:00 PM EST
Drug Induces Morphologic, Molecular and Clinical Remissions in Myelofibrosis
Mayo Clinic

Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

Released: 9-Dec-2013 4:25 PM EST
Gene Sequencing Project Finds Family of Drugs with Promise for Treating Childhood Tumor
St. Jude Children's Research Hospital

Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.

5-Dec-2013 11:00 AM EST
Gene ‘Driver’ of Waldenstrom’s Macroglobulinemia in Up to One-Third of Patients Identified
Dana-Farber Cancer Institute

In nearly one-third of patients with Waldenstrom’s Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology (ASH). The finding may open the way to clinical trials of the drug in Waldenstrom’s patients whose tumor cells carry the mutation.

Released: 9-Dec-2013 8:00 AM EST
How Can We Improve the Efficacy of Antipsychotics in the Era of Personalized Pharmacotherapy?
Universite de Montreal

The clinical context of the administration and dosage of antipsychotics may influence their efficacy, reported Philippe Vincent and Édouard Kouassi, from the Institut universitaire en santé mentale de Montréal and Université de Montréal.

6-Dec-2013 12:50 PM EST
Innovative Drug-Dispensing Contact Lens Delivers Glaucoma MedicationContinuously for a Month
Massachusetts Eye and Ear

Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children’s Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

5-Dec-2013 9:40 AM EST
Novel Drug Regimen Can Improve Stem Cell Transplantation Outcomes
Dana-Farber Cancer Institute

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.

5-Dec-2013 11:00 AM EST
First Kidney-Specific, Mechanism-Based Drug Design Underway
University of Alabama at Birmingham

Changes to a key protein amplified its natural ability to counter kidney disease, according to a study published today by researchers at the University of Alabama at Birmingham in the journal Nature Medicine.

Released: 7-Dec-2013 10:00 AM EST
Jasco/Roswell Park Research on PIM Inhibitors Presented at ASH Annual Meeting
Roswell Park Comprehensive Cancer Center

Jasco Pharmaceuticals and Roswell Park are sharing research results on use of a novel PIM2 inhibitor to overcome multi-drug resistance at the American Society of Hematology (ASH) Annual Meeting.

Released: 6-Dec-2013 2:00 PM EST
Angioplasty May Not Be Better than Drug Therapy in Stable Disease
Stony Brook University

For patients with stable coronary artery disease (CAD) who are not experiencing a heart attack and an abnormal stress test, treatment of their narrowed arteries by the common procedure of angioplasty may not provide additional benefits compared to drug therapy alone. This finding results from a survey of more than 4,000 patients with myocardial ischemia, or inadequate circulation, led by cardiologists at Stony Brook University School of Medicine. The survey results are published in the online first edition of JAMA Internal Medicine.

4-Dec-2013 3:30 PM EST
How Brain Cancer Cells Hide from Drugs
University of California, Los Angeles (UCLA), Health Sciences

• Glioblastoma is the most common and deadly form of brain cancer. • Drugs target specific mutations on the surface of glioblastoma cells. • Glioblastoma cells are able to eliminate the gene mutation to avoid detection when the targeted drug is present. • When the drug is stopped, tumor cells are able to reacquire the gene mutation, which resensitizes them to the drug.

Released: 5-Dec-2013 7:00 AM EST
Database Tracks Toxic Side Effects of Pharmaceuticals
North Carolina State University

Sometimes the cure can be worse than the disease. Pharmaceutical drugs are known for their potential side effects, and now researchers have updated an extensive toxicology database so that it can be used to track information about therapeutic drugs and their unintentional toxic effects.

Released: 3-Dec-2013 1:00 PM EST
Many Patients Have Trouble ID’ing Their Medications
Health Behavior News Service

People who identified their medication by shape, size or color instead of name had poorer adherence and an increased risk of hospitalization, finds a recent study in the Journal of Health Communication: International Perspectives.

Released: 2-Dec-2013 1:00 PM EST
Osteoporosis Drugs Compared for Side Effects, Efficacy in Loyola Study
Loyola Medicine

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research’s annual meeting.

Released: 27-Nov-2013 10:00 AM EST
Breathalyzers Could Test Blood Sugar
Dick Jones Communications

Finger pricks may soon be a thing of the past for diabetics. Researchers at Western New England University have created a breathalyzer that may help control blood sugar by measuring the amount of acetone in the breath.

Released: 20-Nov-2013 5:00 PM EST
New Crizotinib Side-Effect: Reduced Measures of Kidney Function During Treatment (Recovery After)
University of Colorado Cancer Center

A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.

Released: 20-Nov-2013 9:25 AM EST
Probe Measuring Immune Function Can Be Used to Determine Nanoparticle Dosage for Patients
University of North Carolina Health Care System

The development of a probe to measure the body’s immune function could lead to more accurate, individualized doses for cancer patients prescribed nanoparticle-based drugs, according to research conducted at the University of North Carolina.

19-Nov-2013 11:45 AM EST
Sinai Hospital Releases Results Evaluating Antiplatelet Effects of CSL112, A Novel Apolipoprotein A-I Infusion Therapy
LifeBridge Health

Dallas, TX – Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.

19-Nov-2013 9:45 AM EST
Oral Drug May Improve Survival in Men with Metastatic Prostate Cancer
Duke Health

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

Released: 15-Nov-2013 12:00 PM EST
Drug Offers Promising Approach to Improve Outcome for Children with High-Risk Leukemia
St. Jude Children's Research Hospital

Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital.

Released: 14-Nov-2013 1:00 PM EST
New Study May Help Explain Why Some People Taking Drugs for Osteoporosis Are at Risk for Fractures
Texas Biomedical Research Institute

Research with baboons at the Texas Biomedical Research Institute in San Antonio may help explain why some people who take bone-strengthening drugs like bisphosphonates are at-risk for atypical fractures in the long bones in their legs.

6-Nov-2013 9:40 AM EST
Novel Microbicide Gel for Vagina and Rectum Shows Potential for HIV Prevention
American Association of Pharmaceutical Scientists (AAPS)

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).

12-Nov-2013 12:15 PM EST
Mystery Explained: How a Common Chemo Drug Thwarts Graft Rejection in Bone Marrow Transplants
Johns Hopkins Medicine

Results of a Johns Hopkins study may explain why a chemotherapy drug called cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD.

Released: 13-Nov-2013 10:00 AM EST
Could the Next New Cancer Drug Come from Kentucky Coal Mines?
University of Kentucky

In their ongoing quest to develop the latest and most effective drugs for disease treatment, researchers in the University of Kentucky's Center for Pharmaceutical Research and Innovation (CPRI) are looking deep — as in, deep underground.

Released: 12-Nov-2013 10:35 AM EST
Racial Difference in Blood Clotting Warrants a Closer Look at Heart Attack Medications
Thomas Jefferson University

Researchers find a genetic difference in blood clotting mechanisms, which could help explain some of the racial health disparity in heart disease.

7-Nov-2013 1:00 PM EST
Research Offers Way to Disrupt Fibrosis
Saint Louis University Medical Center

Scientists have identified a pathway that regulates fibrosis, suggesting a possible pharmacologic approach to treat patients with a broad range of fibrotic diseases.

6-Nov-2013 8:00 AM EST
Tricking Algae's Biological Clock Boosts Production of Drugs, Biofuels
Vanderbilt University

Tricking algae’s biological clock to remain in its daytime setting can dramatically boost the amount of commercially valuable compounds that these simple marine plants can produce when they are grown in constant light.

31-Oct-2013 1:00 PM EDT
Scientists Unlock Secrets of Diabetes Drug
McMaster University

The key is that metformin doesn’t work to lower blood glucose by directly working on the glucose. It works on reducing harmful fat molecules in the liver, which then allows insulin to work better and lower blood sugar levels.

24-Oct-2013 11:15 AM EDT
A New Weapon in the Fight Against Superbugs
AVS: Science and Technology of Materials, Interfaces, and Processing

Nanoscale images, presented at the AVS Meeting in Long Beach, Calif., may provide ‘hole’ story on pore-making antibiotic peptides

Released: 30-Oct-2013 4:50 PM EDT
Risk of Osteoporosis Drug’s Side Effects Not Significant, Loyola Researchers Find
Loyola Medicine

The risks of developing kidney failure and a calcium deficiency from the popular osteoporosis drug zoledronic acid are extremely rare, according to researchers at Loyola University Health System (LUHS). These findings were presented earlier this month at the American Society for Bone and Mineral Research’s annual meeting.

Released: 29-Oct-2013 1:00 PM EDT
Experimental Drug Shows Promise in Lung Cancer
University of California, Los Angeles (UCLA), Health Sciences

MK-3475, an anti-PD1 immunotherapy drug with promising results in advanced trials in melanoma is also showing potential in lung cancer based on preliminary phase 1b data presented at the 15th World Conference on Lung Cancer in Sydney, Australia. By blocking the PD-1 protein, the drug alerts the immune system to attack the cancer. It is generally well tolerated and further trials in lung cancer are currently underway.

24-Oct-2013 9:35 AM EDT
A Potential New Class of Fast-Acting Antidepressant
University of Chicago Medical Center

More than 1 in 10 Americans take antidepressants, but these medications can take weeks—and for some patients, months—before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.

Released: 28-Oct-2013 11:00 PM EDT
New Drug to Help Common Bowel Disease
University of Adelaide

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

Released: 28-Oct-2013 4:40 PM EDT
Researchers Detail Possible Resistance Mechanisms of Colorectal Cancer to Bevacizumab (Avastin)
University of Colorado Cancer Center

A University of Colorado Cancer Center study published in the journal PLoS One shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab’s blockage of VEGF-A to continue to drive tumor growth.

Released: 25-Oct-2013 12:40 PM EDT
New ALS Drug Headed for Phase II Trial
Houston Methodist

Researchers will soon begin phase IIa clinical trials of TDI-132, a drug that in animal models has shown promise in reducing the inflammation associated with Amyotrophic Lateral Sclerosis.

Released: 25-Oct-2013 10:30 AM EDT
New Study Shows Promise for First Effective Medicine to Treat Cocaine Dependence
University of Maryland School of Medicine

New research published in JAMA Psychiatry reveals that topiramate, a drug approved by the U.S. Food and Drug Administration (FDA) to treat epilepsy and migraine headaches, also could be the first reliable medication to help treat cocaine dependence.

22-Oct-2013 6:00 PM EDT
Yeast, Human Stem Cells Drive Discovery of New Parkinson’s Disease Drug Targets
Whitehead Institute for Biomedical Research

Using a discovery platform whose components range from yeast cells to human stem cells, Whitehead Institute scientists have identified a novel Parkinson’s disease drug target and a compound capable of repairing neurons derived from Parkinson’s patients.

Released: 24-Oct-2013 10:00 AM EDT
Diabetes Drug Metformin with Chemo and Radiation May Improve Outcomes in Lung Cancer Patients
Perelman School of Medicine at the University of Pennsylvania

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

18-Oct-2013 10:00 AM EDT
Stopping Transplant Drugs Before Conception Benefits Fetus
American Society of Nephrology (ASN)

Highlights • Kidney transplant recipients who discontinue immunosuppressive drugs before conception have a higher rate of live births and a lower rate of birth defects without an increased risk of kidney problems.

Released: 21-Oct-2013 1:00 PM EDT
Staurosporine Safely Delivered in Liposomes
UC San Diego Health

Researchers at the University of California, San Diego School of Medicine have discovered a way to effectively deliver staurosporine (STS), a powerful anti-cancer compound that has vexed researchers for more than 30 years due to its instability in the blood and toxic nature in both healthy and cancerous cells.



close
3.3037